Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

http://www.wikidata.org/entity/Q37277238

about

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response.LinkedOmics: analyzing multi-omics data within and across 32 cancer types.The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.The biological significance of histone modifiers in multiple myeloma: clinical applications

P2860

Q26739689-D2F59DB4-7534-4EB7-B1C4-2165BF805DE1 Q42378996-05959DA5-6C07-4674-B753-CC4256CC38DB Q47106278-596B706B-BE3E-40B3-8C3D-E1B91BD3C45D Q55519853-293CC724-F518-4A99-B92D-0900A3C880BE Q58718492-CFD2B546-1D4B-4ED1-AC03-380BACD57A9E

P2860

Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

http://www.wikidata.org/entity/Q37277238

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@en

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@nl

type

label

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@en

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@nl

prefLabel

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@en

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@nl

P1433

Q37277238-F13510D1-8458-4275-B276-BC0F9A1D93A2

P1476

Q37277238-29570319-F21E-424A-9BDE-83D2972BE5BE

P2093

Q37277238-5A69B433-D306-41D8-A141-8A2AD24A000F

Q37277238-5FF9C724-3AAC-4ADA-B743-D5775F2B6AC2

Q37277238-603C6637-B9D3-448B-A9BA-3467F5E2E735

Q37277238-8C769B34-5672-4A7F-841C-4966796F0223

Q37277238-9B63620F-FF10-4C5F-B2AE-6974F99BB4D4

Q37277238-9E03E15B-3DF6-46D6-AF22-2123BB53ADDB

Q37277238-B5330619-ADB4-46E1-97B0-AACA4B248B34

Q37277238-E5D91896-9B25-436E-BA0E-C3CB8C9C4871

Q37277238-EDCB6220-F252-49CB-8160-FECB87155458

Q37277238-F2BA5CDC-FA71-4F46-BFAB-3F6344255C3D

P2860

Q37277238-0503F0AF-550B-4CB6-A202-ED9653D8FADB

Q37277238-056B9D5B-A15F-4808-B15E-98E9311D1F7B

Q37277238-13CB32DC-62A8-4344-94DB-1BA8E36872A1

Q37277238-15981C7C-5002-4996-BE13-48780FF2D54E

Q37277238-15D9987B-9559-4D33-9030-2C3FF93D9E45

Q37277238-170107EB-875E-42AE-BA72-CD90CE2B03F8

Q37277238-17AAFE70-437E-41C6-BA04-58689E453AD3

Q37277238-1B639E1F-ABB3-4AA3-860B-26F16D09CC5E

Q37277238-1FD01578-E55F-458F-8238-BA18B16884FE

Q37277238-24745F95-8143-43DC-845C-D9BF7938264F

P304

Q37277238-7AA933FD-D3FF-4D1A-8CAE-5F40C1B85CDE

P31

Q37277238-09CDDD27-5F80-4869-BDAE-D00959394AD7

P356

Q37277238-1FD62901-B8C1-468B-8371-2B6814A2D807

P433

Q37277238-68E069AD-0188-4770-82DE-5B4C1C349EE8

P478

Q37277238-F0E37A91-48DF-45A2-B3C7-2CFC84A59E42

P577

Q37277238-D34DD0F1-9A88-42DB-A56A-E3CAE8F3A506

P698

Q37277238-4BDB8949-C9DF-4D12-8561-BECB54E309CD

P932

Q37277238-CE6FF93E-68CD-4E72-B132-C66D5F51C223

P356

JCI.INSIGHT.85061

P1433

P1476

Histone deacetylase inhibitor ...... gradation in multiple myeloma.

@en

P2093

Atsuko Deguchi

http://www.w3.org/2001/XMLSchema#string

Eri Ohta

http://www.w3.org/2001/XMLSchema#string

Hideto Tamura

http://www.w3.org/2001/XMLSchema#string

Junji Tanaka

http://www.w3.org/2001/XMLSchema#string

Mariko Ishibashi

http://www.w3.org/2001/XMLSchema#string

Satoko Sunamura

http://www.w3.org/2001/XMLSchema#string

Shu Takeda

http://www.w3.org/2001/XMLSchema#string

Toshiko Motoji

http://www.w3.org/2001/XMLSchema#string

Yan-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Yoichi Imai

http://www.w3.org/2001/XMLSchema#string

P2860

Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

New and emerging HDAC inhibitors for cancer treatment

Lysine acetylation targets protein complexes and co-regulates major cellular functions

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Calcineurin. Structure, function, and inhibition.

P304

e85061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI.INSIGHT.85061

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27699258

http://www.w3.org/2001/XMLSchema#string

P932

5033869

http://www.w3.org/2001/XMLSchema#string